Retrophin Inc (NASDAQ:RTRX) announced positive top-line results from the Phase 2 DUET study of sparsentan for the treatment of focal segmental glomerulosclerosis (FSGS), a …
One of the more anticipated events of early 2015 played out on Friday – detailed results from an early study of Biogen Idec Inc's (NASDAQ:BIIB) experimental …
Just a day after Retrophin Inc. (NASDAQ:RTRX) announced a $100 million financing the U.